Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 616 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Targeted Therapy Cabozantinib Slows Progression of Rare Kidney Cancer March 24, 2021 Workout Wednesday – Leg Stretches Part 2 July 15, 2020 The US National COVID Cohort Collaborative Consortium Provides Real-World Evidence on... March 29, 2022 EMA Recommends Granting a Marketing Authorisation for Tepotinib December 23, 2021 Load more HOT NEWS Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in... Apple Season is Here! After Lung Cancer Screening, Follow-Up Procedures May Be Riskier than Thought Five Questions With…Jae.
